# Holmium-166 TARE in Liver Limited Unresectable Colorectal Cancer Patients

> **NCT06332079** · PHASE2 · TERMINATED · sponsor: **Gruppo Oncologico del Nord-Ovest** · enrollment: 4 (actual)

## Conditions studied

- Colorectal Cancer Metastatic

## Interventions

- **PROCEDURE:** 166Holmium TARE
- **DRUG:** Cetuximab
- **DRUG:** Panitumumab
- **DRUG:** 5-Fluorouracil
- **DRUG:** Bevacizumab
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT06332079
- **Lead sponsor:** Gruppo Oncologico del Nord-Ovest
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-03-13
- **Primary completion:** 2025-12-16
- **Final completion:** 2025-12-16
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Medical devices (QuiremScout/QuiremSpheres) no longer available due to discontinuation of production by the manufacturer
- **Last updated:** 2026-01-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06332079

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06332079, "Holmium-166 TARE in Liver Limited Unresectable Colorectal Cancer Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06332079. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*